Proteins and Peptides

10 Apr 2020 Vigeo Therapeutics Doses First Patients in Expansion Phase of its 1b/2 Study Investigating VT1021 in Patients with CD36 Expressing Cancers
08 Apr 2020 Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
04 Apr 2020 Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU
02 Apr 2020 Ansun Biopharma Announces Positive Results from Investigator-Initiated Trial of Novel COVID-19 Treatment
02 Apr 2020 Synairgen confirms commencement of dosing in trial of SNG001 in COVID-19
02 Apr 2020 FDA Approves Additional Treatment for Adults and Adolescents with Hemophilia A or B and Inhibitors
02 Apr 2020 APEIRON Biologics Initiates Phase II Clinical Trial of APN01 for Treatment of COVID-19
01 Apr 2020 All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study
01 Apr 2020 Mimetogen Pharmaceuticals Completes Enrollment of MIM-728 Phase 3 Trial for Tavilermide for Dry Eye Disease
30 Mar 2020 Zealand Pharma announces positive topline results from Phase 2 trial with dasiglucagon in individuals who have undergone bariatric surgery
26 Mar 2020 Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate Study
22 Mar 2020 Zealand Pharma regains worldwide rights to Amylin analog program from Boehringer Ingelheim
18 Mar 2020 Mallinckrodt Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)
18 Mar 2020 Blue Earth Diagnostics Announces Dosing of First Patient in Phase 3 LIGHTHOUSE Clinical Trial of Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Newly Diagnosed Prostate Cancer
16 Mar 2020 Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis
11 Mar 2020 Airway Therapeutics Announces Filing with NIH to Evaluate AT-100 as a Therapy for Novel Coronavirus
11 Mar 2020 ImmunityBio Announces Durable Virus Control of SHIV Without Anti-Retroviral Therapy by Activating NK and Memory T Cells With N-803, an IL-15 Superagonist
03 Mar 2020 Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson’s Disease
26 Feb 2020 Herantis Pharma Plc Announces Topline Results of Phase 1-2 CDNF Trial
26 Feb 2020 APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China
25 Feb 2020 NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement and
24 Feb 2020 ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis
21 Feb 2020 NoNO Inc. Reports Groundbreaking Results from the Phase 3 ESCAPE-NA1 Study of the Peptide, Nerinetide, in Acute Ischemic Stroke
21 Feb 2020 Cyclo Therapeutics Announces Completion of Enrollment in its Phase I/II Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
20 Feb 2020 Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top